Drug Profile


Alternative Names: AWD 12353; ELB 353

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ASTA Medica
  • Developer Acorda Therapeutics
  • Class Anti-inflammatories; Antiasthmatics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic obstructive pulmonary disease

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease
  • No development reported Hypersensitivity

Most Recent Events

  • 08 Aug 2011 Phase-I development for Chronic obstructive pulmonary disease has been completed
  • 26 Apr 2010 Top-line adverse events and pharmacodynamics data from a phase I trial in volunteers released by Biotie Therapies Corp
  • 14 Sep 2009 Biotie initiates a phase I trial in Healthy volunteers in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top